Erlotinib Recruiting Phase 2 Trials for Sporadic Papillary Renal Cell Cancer / Metastatic Papillary RCC / HLRCC Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01130519A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer